Search This Blog

Monday, February 23, 2026

ImmunityBio reports 700% year-over-year revenue growth

 

 in latest financial results

  • Company highlighted expanded ANKTIVA approvals in conjunction with reporting its latest financial results
  • Company also highlighted global commercial partnerships alongside the announcement of its latest financial results
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)